Utility of non-invasive fibrosis assessment for patients with chronic hepatitis C treated with telaprevir-based triple therapy

Utility of non-invasive fibrosis assessment for patients with chronic hepatitis C treated with telaprevir-based triple therapy - Prediction of treatment outcome by triple therapy using non-invasive fibrosis assessment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012850

Enrollment

100

Registered

2014-01-14

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C patients

Exclusion criteria

Exclusion criteria: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation (Child-Pugh B or C, ascites, bleeding varices, or encephalopathy); (3) other causes of liver disease; (4) excessive active alcohol consumption, drug abuse or severe mental disorder; (5) the presence of active cancer at entry; or (6) treatment with antiviral or immunosuppressive agents prior to enrollment

Design outcomes

Primary

Measure	Time frame
Sustained virological response	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp+81-92-642-5909

Outcome results